Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04108013 | A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC | unknown | Phase 2 | 38 | Xuanwu Hospital, BeijingOTHER | 0 | Sep 27, 2019 | clinicaltrials |
| NCT04106180 | SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC | unknown | Phase 2 | 63 | Fudan UniversityOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT04054531 |
| Study of KN046 With Chemotherapy in First Line Advanced NSCLC |
| unknown |
| Phase 2 |
| 50 |
| Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY |
| 1 |
| Sep 10, 2019 |
| clinicaltrials |
| NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | unknown | Phase 2 | 68 | Hunan Cancer HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT04029350 | Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M(ALTN-03) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04063462 | Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT03972189 | Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 111 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT03983928 | Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT04056949 | Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy | unknown | Phase 2 | 30 | Junling LiOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01823003 | Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases(sbrtlungfff) | unknown | Phase 2 | 67 | Institut Català d'OncologiaOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04023617 | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC | unknown | Phase 2 | 72 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT03987087 | A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC | unknown | Phase 2 | 68 | Guizhou Medical UniversityOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03726736 | Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC(ACWDVDFPTAN) | unknown | Phase 1 / Phase 2 | 97 | Yong FangOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03062800 | Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) | unknown | Phase 2 | 232 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03936621 | Efficacy and Safety of Omega 3 Fatty Acid Supplements on Heavy Smokers(Omega) | unknown | Phase 2 | 42 | British Columbia Cancer AgencyOTHER | 0 | May 7, 2019 | clinicaltrials |
| NCT03647956 | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | unknown | Phase 2 | 40 | The University of Hong KongOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03911193 | CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation(CABinMET) | unknown | Phase 2 | 25 | Fondazione Ricerca TraslazionaleOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03903887 | A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT02605811 | Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer | unknown | Phase 2 | 426 | Guangzhou Medical UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03374280 | Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC | unknown | Phase 2 | 178 | Guangzhou Medical UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03841136 | Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03886441 | Prevention of Locally Advanced NSCLC Radiotherapy Pneumonia by Inhaling Beclomethasone Propionate | unknown | Phase 2 | 194 | Tongji UniversityOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT03874000 | Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients(SMART) | unknown | Phase 2 | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02771314 | Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC | unknown | Phase 2 | 48 | Hellenic Oncology Research GroupOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT02726568 | High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 19, 2019 | clinicaltrials |
| NCT03300115 | Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC | unknown | Phase 2 | 222 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 19, 2019 | clinicaltrials |
| NCT03823807 | A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC | unknown | Phase 2 | 300 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03811054 | The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 60 | Beijing Chest HospitalOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03780283 | Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC | unknown | Phase 2 | 30 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03781869 | Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer | unknown | Phase 2 | 116 | Third Military Medical UniversityOTHER | 0 | Dec 20, 2018 | clinicaltrials |
| NCT03432156 | Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 68 | Beijing Friendship HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03765775 | Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | unknown | Phase 2 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT03732001 | A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC(ALTER-L024) | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT03754530 | Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation | unknown | Phase 2 | 162 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT03750916 | Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer(ACDFNSNSCLC) | unknown | Phase 2 | 46 | Qilu Hospital of Shandong UniversityOTHER | 0 | Nov 26, 2018 | clinicaltrials |
| NCT03751592 | Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer | unknown | Phase 1 / Phase 2 | 144 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., LtdINDUSTRY | 1 | Nov 26, 2018 | clinicaltrials |
| NCT03735264 | Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）(ACDFNSCLC) | unknown | Phase 2 | 46 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Nov 8, 2018 | clinicaltrials |
| NCT03732846 | Anlotinib in Treatment of Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 43 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03728374 | Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma | unknown | Phase 2 | 38 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Nov 2, 2018 | clinicaltrials |
| NCT01788332 | Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)(PIN) | unknown | Phase 2 | 70 | Lisette NixonOTHER_GOV | 1 | Oct 26, 2018 | clinicaltrials |
| NCT03709953 | Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma(Spark-AL003) | unknown | Phase 2 | 33 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT03706703 | Rh-Endostatin (Endostar®) Continuous Intravenous Infusion | unknown | Phase 2 | 50 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03703596 | Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC | unknown | Phase 2 | 88 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02811354 | Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA(PLASMA) | unknown | Phase 2 | 108 | National University Hospital, SingaporeOTHER | 5 | Sep 20, 2018 | clinicaltrials |
| NCT03672136 | Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients | unknown | Phase 2 | 25 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03407300 | A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 2 | 80 | Haining Health-Coming Biotech Co., Ltd.OTHER | 1 | Sep 13, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2019source: clinicaltrials